Citius Pharmaceuticals (id:5456 CTXR)
0.134 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:12:46 AM)
Exchange closed, opens in 1 day 23 hours
0.75 USD (0.75%)
-34.86 USD (-34.86%)
-62.88 USD (-62.88%)
-79.38 USD (-79.38%)
-82.84 USD (-82.84%)
-70.22 USD (-70.22%)
-99.29 USD (-99.29%)
-99.11 USD (-99.11%)
About Citius Pharmaceuticals
Market Capitalization 40.52M
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
| Headquarters (address) |
11 Commerce Drive Cranford 07016 NJ United States |
| Phone | 908 967 6677 |
| Website | https://citiuspharma.com |
| Employees | 22 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | CTXR |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.110 - 1.07 |
| Market Capitalization | 40.52M |
| P/E trailing | -0.608 |
| P/E forward | 1.18 |
| Price/Book | 0.473 |
| Beta | 1.66 |
| EPS | -0.240 |
| EPS United States (ID:6, base:3400) | 24.26 |